Related Experiment Videos

Discovery, Development, and clinical applications of bortezomib

Laura Jung1, Lisa Holle, William S Dalton

  • 1Syntaxx Communications, Inc. Atlanta, Georgia 30097-5906, USA.

Oncology (Williston Park, N.Y.)
|February 4, 2005
PubMed

Insights

Proteasome inhibitors, like bortezomib, offer a targeted cancer therapy by disrupting protein destruction in tumor cells. This novel approach shows promise in treating multiple myeloma and other cancers, with ongoing research exploring its full potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Proteasome inhibition represents a novel therapeutic strategy in cancer treatment.
  • Proteasome inhibitors disrupt the degradation of regulatory proteins crucial for tumor growth and metastasis.
  • This disruption leads to protein imbalance, inhibiting cell replication and inducing apoptosis.

Purpose of the Study:

  • To evaluate the efficacy and safety of bortezomib (PS-341, Velcade) as a proteasome inhibitor in cancer therapy.
  • To review preclinical and clinical study results of bortezomib in various hematologic malignancies and solid tumors.
  • To identify potential prognostic factors for bortezomib treatment response.

Main Methods:

  • Review of preclinical data demonstrating bortezomib's effects on tumor cell growth, apoptosis, chemoresistance, and angiogenesis.
  • Analysis of Phase I and II clinical trial results for bortezomib in patients with advanced hematologic malignancies and solid tumors.
  • Examination of evidence regarding prognostic factors influencing treatment outcomes in multiple myeloma.

Main Results:

  • Bortezomib demonstrated antitumor activity by suppressing tumor growth, inducing apoptosis, overcoming resistance, and inhibiting angiogenesis in preclinical studies.
  • Phase I studies confirmed bortezomib's antitumor activity in advanced cancers, often without additive toxicities.
  • Phase II studies supported bortezomib's efficacy in relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma, with varied results in renal cell cancer.

Conclusions:

  • Bortezomib is an effective proteasome inhibitor approved for refractory/relapsed multiple myeloma.
  • Further research is necessary to define optimal bortezomib regimens for diverse tumor types and identify predictive prognostic indicators.
  • Ongoing studies are investigating bortezomib in earlier stages of multiple myeloma, including first-line therapy.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...